My thanks to David Haselhurst ( aka The Speculator in the Bulletin ) who first alerted me to Viralytics yonks ago .
I am disappointed in the offer by Merck , ( I believe that when the April results are released , the true value of Cavatak will be realised ). But a profit , and a good profit , is a profit and sure beats the alternative .And I will be taking mine . A counter offer is a bonus .
